The effect of intrathyroidal versus intraperitoneal bevacizumab on thyroid volume and vasculature flow in a rat model.
Bevacizumab
thyroid
ultrasound
Journal
Gland surgery
ISSN: 2227-684X
Titre abrégé: Gland Surg
Pays: China (Republic : 1949- )
ID NLM: 101606638
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
23
7
2019
pubmed:
23
7
2019
medline:
23
7
2019
Statut:
ppublish
Résumé
Several clinical conditions increase thyroid gland vascularity, impacting surgical blood loss. Bevacizumab has been observed to reduce thyroid function, possibly through its effect on gland angiogenesis. This study aimed to determine if bevacizumab has any effect on thyroid vascularity as measured by gland volume and superior thyroid artery (STA) flow velocity in the normal rat thyroid. Sixteen adult female Sprague-Dawley rats were placed under general anesthesia to measure baseline thyroid gland characteristics. A Vevo 2100 high-frequency ultrasound with 40 mHz transducer was used to obtain STA flow measurements and thyroid gland dimensions. Four rats served as controls. Six rats received intrathyroidal (IT) injections and 6 received intraperitoneal (IP) injections of bevacizumab (4-5 mg/kg). After two weeks ultrasound measurements were repeated. Pretreatment animals displayed similar thyroid volume and vascularity. Thyroid volume decreased (62.583 Single systemic administration of bevacizumab appears to decrease thyroid volume without an effect on STA flow, VEGF or CD31 staining. These preliminary findings support further study of pharmacologic intervention in thyroid conditions characterized by increased angiogenesis and vascularity, such as iodine deficiency, Graves disease, and hypothyroidism.
Sections du résumé
BACKGROUND
BACKGROUND
Several clinical conditions increase thyroid gland vascularity, impacting surgical blood loss. Bevacizumab has been observed to reduce thyroid function, possibly through its effect on gland angiogenesis. This study aimed to determine if bevacizumab has any effect on thyroid vascularity as measured by gland volume and superior thyroid artery (STA) flow velocity in the normal rat thyroid.
METHODS
METHODS
Sixteen adult female Sprague-Dawley rats were placed under general anesthesia to measure baseline thyroid gland characteristics. A Vevo 2100 high-frequency ultrasound with 40 mHz transducer was used to obtain STA flow measurements and thyroid gland dimensions. Four rats served as controls. Six rats received intrathyroidal (IT) injections and 6 received intraperitoneal (IP) injections of bevacizumab (4-5 mg/kg). After two weeks ultrasound measurements were repeated.
RESULTS
RESULTS
Pretreatment animals displayed similar thyroid volume and vascularity. Thyroid volume decreased (62.583
CONCLUSIONS
CONCLUSIONS
Single systemic administration of bevacizumab appears to decrease thyroid volume without an effect on STA flow, VEGF or CD31 staining. These preliminary findings support further study of pharmacologic intervention in thyroid conditions characterized by increased angiogenesis and vascularity, such as iodine deficiency, Graves disease, and hypothyroidism.
Identifiants
pubmed: 31328099
doi: 10.21037/gs.2018.09.12
pii: gs-08-03-212
pmc: PMC6606475
doi:
Types de publication
Journal Article
Langues
eng
Pagination
212-217Déclaration de conflit d'intérêts
Conflicts of Interest: Other Presentations—This manuscript was given as a poster presentation at that American Academy of Otolaryngology Head and Neck Surgery Annual Meeting in Chicago, IL, USA.
Références
J Endocrinol. 2005 Apr;185(1):111-9
pubmed: 15817832
Anat Histol Embryol. 1991 Dec;20(4):289-98
pubmed: 1665679
J Clin Endocrinol Metab. 2007 Jun;92(6):2182-9
pubmed: 17389702
Laryngoscope. 2007 Apr;117(4):674-9
pubmed: 17429874
Cancer. 2010 Feb 15;116(4 Suppl):1053-8
pubmed: 20127950
Thyroid. 2013 Oct;23(10):1329-30
pubmed: 23548042
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12018-23
pubmed: 23818623
J Reprod Dev. 2015;61(3):219-27
pubmed: 25797533
Thyroid. 2015 Jul;25(7):823-9
pubmed: 25873398